カテゴリ： GlobalData, イギリス, 企業調査

GlaxoSmithKline Plc (GSK)：医療機器：M&Aディール及び事業提携情報

◆英語タイトル：GlaxoSmithKline Plc (GSK) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA904C7262
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：162
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イギリス
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
GlaxoSmithKline Plc (GSK) is a healthcare company, which focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of HIV, respiratory, cancer, immuno-inflammation, anti-virals, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio cover various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

GlaxoSmithKline Plc (GSK) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
GlaxoSmithKline Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 8
GlaxoSmithKline Plc, Medical Equipment Deals By Type, 2012 to YTD 2018 9
GlaxoSmithKline Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 10
GlaxoSmithKline Plc, Medical Equipment, Deals By Market, 2012 to YTD 2018 11
GlaxoSmithKline Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 12
GlaxoSmithKline Plc, Medical Equipment, Deal Details 17
Venture Financing 17
23andMe to Raise up to USD300 Million in Financing 17
Reciprocal Labs (Propeller Health) Secures USD20 Million in Venture Funding 18
NeuSpera Medical Raises USD26 Million in Series B Financing Round 20
SetPoint Medical Raises USD30 Million in Series D Financing 21
Saluda Medical Raises USD39.4 Million in Series D Financing 23
Progyny Raises Additional USD10 Million in Series B Financing 24
ZappRx Secures USD25 Million in Series B Funding 25
SetPoint Medical Raises Funds through Venture Financing 26
Propeller Health Raises USD21.5 Million in Series C Financing 28
CVRx Raises USD57.7 Million in Series G Financing 29
Cala Health Raises USD18 Million in Series A Financing Round 31
Setpoint Medical Raises Additional USD15 Million in Series C Venture Financing 33
Avhana Health Raises USD0.7 Million in Seed Financing 35
Progyny Raises Additional Funds through Venture Financing 36
ZappRx Raises USD5.6 Million in Series A Financing 37
HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 38
ZappRx Raises US$2 Million In Seed Financing 39
Setpoint Medical Raises US$27 Million In Venture Financing 40
Health XL Raises Funds Through Venture Financing 41
HTG Molecular Diagnostics Raises US$7.5 Million In Series E Financing 42
SR One Plans To Invest In Biotechnology Company 43
IlluminOss Medical Raises US$28 Million In Series C Financing 44
Auxogyn Raises US$18 Million In Series B Financing 46
Partnerships 48
Covance Enters into Strategic Technology Agreement with GlaxoSmithKline 48
NeuroMetrix to Enter into Agreement with GlaxoSmithkline Consumer Healthcare 49
Owlstone Medical Enters into Co-Development Agreement with GlaxoSmithKline 50
EnteroMedics Enters into Agreement with Galvani Bioelectronics 51
GlaxoSmithKline to Form Joint Venture with Verily Life Sciences 52
GlaxoSmithKline May Form Joint Venture with Qualcomm 53
Propeller Health Expands Agreement with GlaxoSmithKline 54
Thermo Fisher Scientific Enters into Co-Development Agreement with GlaxoSmithKline and Pfizer 55
Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK 56
Feinstein Institute For Medical Research Enters Into Research Agreement With GSK, University of Pennsylvania And MIT 57
AB-Biotics Enters Into Co-Promotion Agreement With GlaxoSmithKline For Neurofarmagen 59
KineMed Enters Into Co-Development Agreement With GlaxoSmithKline 60
Epistem Holdings Enters Into Co-Development Agreement With GlaxoSmithKline 61
Siemens Healthcare Diagnostics Enters Into Co-Development Agreement With ViiV Healthcare 62
Ionis Pharmaceuticals Enters Into Licensing Agreement with Glaxo Group and GlaxoSmithKline 63
Equity Offering 64
Response Genetics Completes Private Placement Of Shares For US$9 Million 64
Debt Offering 65
GlaxoSmithKline Raises USD1.19 Billion in Public Offering of 1.25% Bonds Due 2026 65
GlaxoSmithKline Raises USD897.1 Million in Public Offering of Bonds Due 2020 66
GlaxoSmithKline Raises USD897.1 Million in Public Offering of 1.75% Bonds Due 2030 67
GlaxoSmithKline Raises USD1.25 Billion in Public Offering of 3.375% Bonds Due 2023 68
GlaxoSmithKline Raises USD0.75 Billion in Public Offering of Bonds Due 2021 69
GlaxoSmithKline Raises USD1.75 Billion in Public Offering of 3.875% Bonds Due 2028 70
GlaxoSmithKline Raises USD1.25 Billion in Public Offering of 3.125% Bonds Due 2021 71
GlaxoSmithKline Raises USD1 Billion in Public Offering of 3.625% Bonds Due 2025 72
GlaxoSmithKline Raises USD832.8 Million in Public Offering of Bonds Due 2026 73
GlaxoSmithKline Raises USD1,428 Million in Public Offering of Bonds Due 2020 74
Asset Transactions 75
Sinclair IS Pharma Acquires Atlean From Stiefel Labs 75
Acquisition 76
GlaxoSmithKline Acquires Remaining 36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD13 Billion 76
GlaxoSmithKline May Acquire Vectura for USD1.62 Billion 78
Teleflex Acquires Semprus BioSciences For Up To USD80 Million 79
GlaxoSmithKline Plc – Key Competitors 81
GlaxoSmithKline Plc – Key Employees 82
GlaxoSmithKline Plc – Locations And Subsidiaries 83
Head Office 83
Other Locations & Subsidiaries 83
Joint Venture 96
Recent Developments 98
Strategy And Business Planning 98
Oct 30, 2017: GSK opens new regional headquarters for Asia in Singapore 98
Feb 16, 2017: GSK and EMBL have signed an agreement to enhance understanding of disease and drug mechanisms 99
Financial Announcements 100
Jul 25, 2018: GSK delivers improvements in sales, margins and cash flow in Q2 2018 100
Feb 07, 2018: GSK delivers improvements in sales, margins and cash flow in 2017 103
Oct 25, 2017: GSK delivers Q3 sales of £7.8 billion, +4% AER, +2% CER 104
Jul 26, 2017: GSK delivers further progress in Q2 and sets out new priorities for the Group 116
Apr 26, 2017: GSK delivers another quarter of continued progress 122
Feb 08, 2017: GlaxoSmithKline: Results announcement for the fourth quarter 2016 125
Corporate Communications 141
Aug 07, 2018: Iain Mackay appointed GSK Chief Financial Officer 141
Jul 12, 2018: James Ford appointed GSK General Counsel 142
Jun 12, 2018: GSK announces changes to Vaccines and Global Manufacturing & Supply leadership 143
May 09, 2018: Simon Dingemans, Chief Financial Officer, to retire from GSK 144
Apr 18, 2018: GlaxoSmithKline Names Kevin Sin as new Senior Vice President and Head of Worldwide Business Development for Research & Development 145
Jan 09, 2018: Representative Director and President of GlaxoSmithKline Corporation Personnel notice 146
Nov 08, 2017: Patrick Vallance, President, R&D, GSK to become UK Government’s Chief Scientific Adviser 147
Nov 08, 2017: Dr Hal Barron appointed Chief Scientific Officer and President, Research & Development, GSK 148
Jul 25, 2017: Karenann Terrell appointed Chief Digital & Technology Officer, GSK 149
Jul 21, 2017: GSK announces Board and Committee changes 150
Jun 19, 2017: GSK confirms start date for Luke Miels 151
Apr 04, 2017: GSK responds to Cyclone Debbie 152
Jan 20, 2017: Luke Miels will succeed Abbas Hussain as President, Global Pharmaceuticals, GSK 153
Jan 19, 2017: Abbas Hussain to leave GSK 154
Jan 19, 2017: Luke Miels appointed President, Global Pharmaceuticals, GSK 155
Legal and Regulatory 156
Feb 23, 2018: GSK, Ministry of Economy, Trade and Industry “Superior Health and Good Management Act 2018 (White 500)” for 2 consecutive years certified 156
Product News 157
Sep 13, 2018: IN(3D)USTRY to gather the latest 3D-printing medical applications 157
Jul 09, 2018: Microsoft and Partners Showcase a New ‘Molecule’ for Better Health Outcomes 158
Feb 05, 2018: Amiko receives CE mark for three novel inhaler sensors 159
Other Significant Developments 160
Oct 24, 2017: COPD Foundation, Geisinger, GSK, and Jvion Team Together to Help COPD Patients 160
Aug 30, 2017: GSK responds to UK Life Sciences Industrial Strategy 161
Appendix 162
Methodology 162
About GlobalData 162
Contact Us 162
Disclaimer 162

List of Tables
GlaxoSmithKline Plc, Medical Equipment, Key Facts, 2017 2
GlaxoSmithKline Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
GlaxoSmithKline Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 8
GlaxoSmithKline Plc, Medical Equipment Deals By Type, 2012 to YTD 2018 9
GlaxoSmithKline Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 10
GlaxoSmithKline Plc, Deals By Market, 2012 to YTD 2018 11
GlaxoSmithKline Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 12
23andMe to Raise up to USD300 Million in Financing 17
Reciprocal Labs (Propeller Health) Secures USD20 Million in Venture Funding 18
NeuSpera Medical Raises USD26 Million in Series B Financing Round 20
SetPoint Medical Raises USD30 Million in Series D Financing 21
Saluda Medical Raises USD39.4 Million in Series D Financing 23
Progyny Raises Additional USD10 Million in Series B Financing 24
ZappRx Secures USD25 Million in Series B Funding 25
SetPoint Medical Raises Funds through Venture Financing 26
Propeller Health Raises USD21.5 Million in Series C Financing 28
CVRx Raises USD57.7 Million in Series G Financing 29
Cala Health Raises USD18 Million in Series A Financing Round 31
Setpoint Medical Raises Additional USD15 Million in Series C Venture Financing 33
Avhana Health Raises USD0.7 Million in Seed Financing 35
Progyny Raises Additional Funds through Venture Financing 36
ZappRx Raises USD5.6 Million in Series A Financing 37
HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 38
ZappRx Raises US$2 Million In Seed Financing 39
Setpoint Medical Raises US$27 Million In Venture Financing 40
Health XL Raises Funds Through Venture Financing 41
HTG Molecular Diagnostics Raises US$7.5 Million In Series E Financing 42
SR One Plans To Invest In Biotechnology Company 43
IlluminOss Medical Raises US$28 Million In Series C Financing 44
Auxogyn Raises US$18 Million In Series B Financing 46
Covance Enters into Strategic Technology Agreement with GlaxoSmithKline 48
NeuroMetrix to Enter into Agreement with GlaxoSmithkline Consumer Healthcare 49
Owlstone Medical Enters into Co-Development Agreement with GlaxoSmithKline 50
EnteroMedics Enters into Agreement with Galvani Bioelectronics 51
GlaxoSmithKline to Form Joint Venture with Verily Life Sciences 52
GlaxoSmithKline May Form Joint Venture with Qualcomm 53
Propeller Health Expands Agreement with GlaxoSmithKline 54
Thermo Fisher Scientific Enters into Co-Development Agreement with GlaxoSmithKline and Pfizer 55
Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK 56
Feinstein Institute For Medical Research Enters Into Research Agreement With GSK, University of Pennsylvania And MIT 57
AB-Biotics Enters Into Co-Promotion Agreement With GlaxoSmithKline For Neurofarmagen 59
KineMed Enters Into Co-Development Agreement With GlaxoSmithKline 60
Epistem Holdings Enters Into Co-Development Agreement With GlaxoSmithKline 61
Siemens Healthcare Diagnostics Enters Into Co-Development Agreement With ViiV Healthcare 62
Ionis Pharmaceuticals Enters Into Licensing Agreement with Glaxo Group and GlaxoSmithKline 63
Response Genetics Completes Private Placement Of Shares For US$9 Million 64
GlaxoSmithKline Raises USD1.19 Billion in Public Offering of 1.25% Bonds Due 2026 65
GlaxoSmithKline Raises USD897.1 Million in Public Offering of Bonds Due 2020 66
GlaxoSmithKline Raises USD897.1 Million in Public Offering of 1.75% Bonds Due 2030 67
GlaxoSmithKline Raises USD1.25 Billion in Public Offering of 3.375% Bonds Due 2023 68
GlaxoSmithKline Raises USD0.75 Billion in Public Offering of Bonds Due 2021 69
GlaxoSmithKline Raises USD1.75 Billion in Public Offering of 3.875% Bonds Due 2028 70
GlaxoSmithKline Raises USD1.25 Billion in Public Offering of 3.125% Bonds Due 2021 71
GlaxoSmithKline Raises USD1 Billion in Public Offering of 3.625% Bonds Due 2025 72
GlaxoSmithKline Raises USD832.8 Million in Public Offering of Bonds Due 2026 73
GlaxoSmithKline Raises USD1,428 Million in Public Offering of Bonds Due 2020 74
Sinclair IS Pharma Acquires Atlean From Stiefel Labs 75
GlaxoSmithKline Acquires Remaining 36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD13 Billion 76
GlaxoSmithKline May Acquire Vectura for USD1.62 Billion 78
Teleflex Acquires Semprus BioSciences For Up To USD80 Million 79
GlaxoSmithKline Plc, Key Competitors 81
GlaxoSmithKline Plc, Key Employees 82
GlaxoSmithKline Plc, Other Locations 83
GlaxoSmithKline Plc, Subsidiaries 84
GlaxoSmithKline Plc, Joint Venture 96

List of Figures
GlaxoSmithKline Plc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
GlaxoSmithKline Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
GlaxoSmithKline Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
GlaxoSmithKline Plc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
GlaxoSmithKline Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 8
GlaxoSmithKline Plc, Medical Equipment, Deals by Type, 2012 to YTD 2018 9
GlaxoSmithKline Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 10
GlaxoSmithKline Plc, Medical Equipment, Deals by Market, 2012 to YTD 2018 11

★海外企業調査レポート[GlaxoSmithKline Plc (GSK)：医療機器：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Crown Bioscience Inc：企業のM&A・事業提携・投資動向
    Crown Bioscience Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Crown Bioscience Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • NanoViricides Inc (NNVC)：企業の財務・戦略的SWOT分析
    Summary NanoViricides Inc (NanoViricides) is a nano-biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening viral infections. The company offers nanoviricide drug candidates against epidemic influenzas and bir …
  • Group Five Ltd：企業の戦略的SWOT分析
    Group Five Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Havells India Ltd (HAVELLS)：電力：M&Aディール及び事業提携情報
    Summary Havells India Limited (Havells) is a fast moving electrical goods (FMEG) company that primarily designs, produces, distributes and sells a range of industrial and consumer electrical products. Its offers various consumer support and industrial electrical solutions support related products. T …
  • Technogenetics srl：医療機器：M&Aディール及び事業提携情報
    Summary Technogenetics srl (Technogenetics), a subsidiary of Shanghai Kehua Bio-engineering Co Ltd, is an immunodiagnostics and molecular genetics company that offers reagents and instruments in the field of biotechnology and pharmacology. The company provides immunodiagnostics products in the areas …
  • Alexander Forbes Group Holdings Ltd (AFH)：企業の財務・戦略的SWOT分析
    Alexander Forbes Group Holdings Ltd (AFH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Formula Pharmaceuticals Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Formula Pharmaceuticals Inc (Formula Pharmaceuticals) is a biopharmaceutical company that develops chimeric antigen receptor immunotherapy for oncology and autoimmune diseases. The company provides its pipeline products such as CIK-CAR.CD19, used as B-lymphocyte surface antigen; CIK-CAR.CD33 …
  • Indiana University Research & Technology Corp：製薬・医療：M&Aディール及び事業提携情報
    Summary Indiana University Research & Technology Corp (IURTC), a subsidiary of Indiana University, is a non-profit company that handles intellectual property, trademarks, and business development activities. The company offers solutions such as technology commercialization, which include disclosure, …
  • Mahle GmbH：企業の戦略的SWOT分析
    Mahle GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • MiMedx Group Inc (MDXG)：企業の財務・戦略的SWOT分析
    Summary MiMedx Group Inc (MiMedx) develops, manufactures and markets regenerative biologics utilizing human placental allografts. The company provides products such as amniotic membrane, umbilical cord, placental ECM and amniotic fluid. It utilizes proprietary purion process that separates placental …
  • Bachem Holding AG (BANB)：製薬・医療：M&Aディール及び事業提携情報
    Summary Bachem Holding AG (Bachem) is a technology-based biochemical company which develops and manufactures peptides and complex organic molecules including active pharmaceutical ingredients and biochemicals for research purposes. Bachem offers its products and services to the pharmaceutical and bi …
  • Dong-A Socio Holdings Co Ltd (000640)：企業の財務・戦略的SWOT分析
    Dong-A Socio Holdings Co Ltd (000640) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Republic Services, Inc.：企業の戦略・SWOT・財務情報
    Republic Services, Inc. - Strategy, SWOT and Corporate Finance Report Summary Republic Services, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Parker Hannifin Corporation (PH)-医療機器分野：企業M&A・提携分析
    Summary Parker Hannifin Corporation (Parker) is a manufacturer of motion and control technologies and systems. The company offers critical motion and control solutions including fluid power systems, electromechanical controls and related components. Its products find use in various industries and ap …
  • LifeNet Health Inc：医療機器：M&Aディール及び事業提携情報
    Summary LifeNet Health Inc (LifeNet Health) is a non-profit organization that specializes in regenerative medicine. It offers allograft bio-implants and organs for transplantation. The organization specializes in offering organ procurement, tissue banking and transplant services. It provides allogra …
  • Ferranti Computer Systems N.V.：戦略・SWOT・企業財務分析
    Ferranti Computer Systems N.V. - Strategy, SWOT and Corporate Finance Report Summary Ferranti Computer Systems N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Compugen Ltd.：企業のM&A・事業提携・投資動向
    Compugen Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Compugen Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Forum Energy Technologies, Inc.：戦略・SWOT・企業財務分析
    Forum Energy Technologies, Inc. - Strategy, SWOT and Corporate Finance Report Summary Forum Energy Technologies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Unilever N.V.：戦略・SWOT・企業財務分析
    Unilever N.V. - Strategy, SWOT and Corporate Finance Report Summary Unilever N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Boryung Medience Corp：企業の戦略・SWOT・財務分析
    Boryung Medience Corp - Strategy, SWOT and Corporate Finance Report Summary Boryung Medience Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆